{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-012464","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.038251+00:00","generated_at":"2026-06-19T08:48:52.498525+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ABVC BioPharma fails to regain Nasdaq bid-price compliance by Feb 14; granted extension to Aug 14, 2023","bullets":["Company missed initial Feb 14, 2023 deadline to close at $1.00 for 10 consecutive business days.","Nasdaq granted an additional 180-day compliance period, now expiring August 14, 2023.","If bid price closes at $1.00 or more for 10 consecutive days before Aug 14, compliance confirmed.","Failure to regain compliance by Aug 14 could lead to delisting; Company may appeal.","Common stock continues trading on Nasdaq Capital Market under symbol ABVC in the interim."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-012464","json":"https://secwatch.observer/filing/0001213900-23-012464.json","markdown":"https://secwatch.observer/filing/0001213900-23-012464.md","text":"https://secwatch.observer/filing/0001213900-23-012464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023012464/0001213900-23-012464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023012464/ea173774-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:48:52.498525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cea4e7582cf4428cf6a890153a966865bc1a49ff","claim":"ABVC BIOPHARMA, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"August 19, 2022, ABVC BioPharma, Inc. (the “ Company ”) filed a Current Report on Form 8-K to report that it received a deficiency letter from the Nasdaq Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“ Rule 5550(a)(2) ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Compan","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023012464/0001213900-23-012464-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}